Akouos IPO Presentation Deck

AK-OTOF Has the Potential to Address an Unmet Need for Individuals with OTOF-Mediated Hearing Loss • Patients typically born deaf • Currently no approved pharmacologic therapies to address OTOF-Mediated hearing loss 28 Only treatment option is cochlear implants Hair Cell Neuron Vesicle CONFIDENTIAL Hair Cell Synapse Neuron Neurotransmitter AKQUOS Vesicle Otoferlin --SL Synapse. Otoferlin is required for the release of neurotransmitters at the junction of the inner hair cells and the spiral ganglion neurons, which carry acoustic information to the brain

View entire presentation